Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
APC
REST API REST API
Homo sapiens
APC is differentially expressed in 335 experiments: 194 organism parts: bone marrow, liver, ... (192 more);, 266 disease states: normal, control, ... (264 more);, 103 cell types 429 cell lines 45 compound treatments and 91 other conditions.
Synonyms DP2, DP3, DP2.5
Orthologs Q4A1V5_CHICK (Gallus gallus)   apc (Danio rerio)   Apc (Rattus norvegicus)   Apc (Mus musculus)   APC (Bos taurus)   Apc (Drosophila melanogaster)   Apc2 (Drosophila melanogaster)   apc (Xenopus laevis)   APC (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, cell migration, pattern specification process, plasma membrane, positive regulation of cell division, microtubule plus-end binding, establishment or maintenance of cell polarity, microtubule binding, protein binding, apoptosis, cell-cell adherens junction, cytoskeleton, stem cell maintenance, kinetochore, cytoplasm, beta-catenin binding, muscle cell homeostasis, cytoplasmic microtubule organization, axis specification, negative regulation of cell proliferation, negative regulation of apoptosis, tight junction, cell cycle arrest, negative regulation of microtubule depolymerization, protein complex assembly, cell junction, proximal/distal pattern formation, positive regulation of apoptosis, negative regulation of Wnt receptor signaling pathway, protein kinase regulator activity, cell adhesion, neuron projection, Wnt receptor signaling pathway, centrosome, neuron projection development, microtubule, regulation of cell cycle, protein kinase binding, nucleus, cell projection, positive regulation of microtubule polymerization, regulation of cell migration, cytoplasmic microtubule, lamellipodium, somatic stem cell maintenance, canonical Wnt receptor signaling pathway, cytokinesis after mitosis, growth cone, regulation of cell differentiation, response to drug, synapse, axonogenesis, binding, response to DNA damage stimulus, negative regulation of MAPKKK cascade, negative regulation of epithelial cell proliferation, lateral plasma membrane, negative regulation of cyclin-dependent protein kinase activity, chromosome organization, mitotic cell cycle spindle assembly checkpoint, regulation of apoptosis, dorsal/ventral pattern formation, neuronal cell body, beta-catenin destruction complex, positive regulation of cell adhesion, regulation of epithelial cell differentiation, negative regulation of epithelial cell proliferation involved in prostate gland development, hair follicle development, negative regulation of odontogenesis, kidney development, mitotic metaphase/anaphase transition, regulation of nitrogen compound metabolic process, positive regulation of protein catabolic process, axon part, positive regulation of cell migration, gamma-catenin binding, cell projection membrane, positive regulation of pseudopodium assembly, pancreas development, retina development in camera-type eye, positive regulation of cell differentiation, regulation of osteoblast differentiation, skin development, regulation of osteoclast differentiation, regulation of microtubule-based process, positive regulation of epithelial cell differentiation, thymus development, negative regulation of canonical Wnt receptor signaling pathway, Axin-APC-beta-catenin-GSK3B complex, regulation of attachment of spindle microtubules to kinetochore, ruffle membrane, tight junction assembly, T cell differentiation in thymus, axonal growth cone, cellular component disassembly involved in apoptosis, microtubule plus end, APC-Axin-1-beta-catenin complex, anterior/posterior pattern specification
InterPro Term Armadillo, SAMP, EB1-bd, APC_15aa_rpt, APC_basic_dom, APC_Cys-rich_rpt
UniProt Accession A1YIQ7, Q9UM98, A5HB97, A5HB96, A5HB94, A5HB95, D6RFL6, Q9HAW6, A1YR11, B2ZRG1, B2ZRE1, P25054, Q4LE70, A5JUM8, B7Z2B6, Q9P119, E7EMH9, E9PFT7
Gene-Disease Assocation DESMOID DISEASE, HEREDITARY, HEPATOCELLULAR CARCINOMA, GASTRIC CANCER, MISMATCH REPAIR CANCER SYNDROME, GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC, COLORECTAL CANCER; CRC, MEDULLOBLASTOMA; MDB, ADENOMATOUS POLYPOSIS OF THE COLON; APC
Search EB-eye ENSG00000134982
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (43 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
HT1080
2
E-MTAB-37, E-GEOD-20089
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
HL-60
1
2
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
423 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (50 experiments)

Factor Value U/D Experiments
2
2
E-TABM-145, E-TABM-130
fibroblast
2
E-GEOD-3920, E-GEOD-26672
macrophage
1
2
E-GEOD-360, E-GEOD-22373, E-GEOD-8286
cardiac myocyte
1
E-MTAB-25
activated natural killer cell (supplemented for IL2 for 24 hours)
1
E-TABM-702
spheroid
1
E-GEOD-4219
97 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-GEOD-12254, ... (78 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-62, E-MTAB-37, E-GEOD-2514, E-MEXP-231
glioblastoma
1
4
E-GEOD-4290, E-MTAB-62, E-MTAB-37, E-GEOD-4412, E-MEXP-567 ... (5 experiments)
sarcoma
3
E-MTAB-37, E-GEOD-2719, E-MTAB-62
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
neuroblastoma
2
E-MTAB-37, E-MTAB-62
260 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, E-GEOD-3720, ... (31 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
none
5
6
E-TABM-868, E-GEOD-412, E-GEOD-2803, E-GEOD-5824, E-GEOD-5741, ... (11 experiments)
valproic acid
1
E-GEOD-1615
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
sevoflurane
1
E-GEOD-4386
selenium
1
E-MEXP-1327
39 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
28 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-860, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-TABM-145, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-22148, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-MTAB-108, ... (8 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-321, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-3720, ... (44 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896, E-GEOD-17204

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.501 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM